RTP-based T3D Therapeutics, which is developing a treatment for Alzheimer’s that has the potential to slow, stop or reverse the course of the disease, has raised more than $700,000 of $1 million debt offering, according to a filing with the US Securities and Exchange Commission.
The company raised the $711,220 from 30 investors. It previously raised more than $2 million in equity.
The company says its lead drug candidate, T3D-959, is a potential “first-in-class” and “best-in-class” disease modifying, breakthrough medicine for treating Alzheimer’s. According to the company, it acts in a multi-faceted manner; the drug addresses and improves the most important defects of Alzheimer’s disease that cause the starvation and the strangulation.
Orally delivered, in pre-clinical trials the drug modified the disease. It is aimed at patients with mild to moderate disease severity.
In early animal trials, T3D-959 showed the potential to reverse memory loss and improve motor function, such as walking. In a small human trial, they found similar results with a good safety profile.
Rather than attack plaques, the sticky white build up clouding neurons in the brain, the T3D drug is designed to attack the Alzheimer brain’s inability to process sugar.
“(The brain) is not processing glucose,” CEO John Didsbury said in a previous interview with WRAL, which included a video.
“That is likely due to insulin resistance and insulin-like growth factor resistance.” It is like diabetes of the brain.
Didsbury said the company believes its drug offers a new ray of hope.”
